BriaCell Therapeutics

BriaCell Therapeutics

Biotechnology
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company’s targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

$28.3M

Market Cap • 10/9/2026

2006

(20 years)

Founded

2023

(3 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Canada

Canada

Country

Valuation

P/B

1,2

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

3,3

EPS

—

Market Cap

Market Cap

28,3M

EV

5,5M

EV/Revenue

0

EV/EBITDA

-0,2

EV/EBIT

-0,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-146,1%

Total Yield

-146,1%

Payout

0%

Retained Earnings

-134,3M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

1,3%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

37,5%

Leverage

N.D./EBITDA

0,8

Debt/Equity

0%

Current Ratio

7,1

Quick Ratio

7,1

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium